BioCentury
ARTICLE | Company News

EU approval for Synthon's generic Copaxone

October 5, 2017 9:49 PM UTC

Synthon B.V. (Nijmegen, the Netherlands) and partner Alvogen Inc. (Pine Brook, N.J.) said a 40 mg/mL formulation of Remurel glatiramer acetate, their generic version of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), received European approval to treat relapsing forms of multiple sclerosis.

Alvogen spokesperson Halldor Kristmannsson told BioCentury the partners plan to launch the 40 mg/mL formulation, the first approved thrice-weekly Copaxone generic in Europe, “as early as possible depending on ongoing litigation” at a “much more affordable price” than Copaxone...